RxDoctor Payments Data

Melanie Sivley

Optometrist · Birmingham, ALNPI 1407859531

Payments from drug & device makers

$2,082in general payments, 2019–2025

Across 71 payments — averaging $29.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$583
  • Alcon$546
  • Genentech, Inc.$172
  • Biotissue Holdings Inc.$149
  • Glaukos Corporation$101
  • Oyster Point Pharma, Inc.$100
  • plus $431 from 11 others

What the payments were for

  • Food & beverage$2,082100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,082 in reported general payments places this provider in the 70th percentile of 749 optometrist providers in Alabama.

See all optometrist providers in Alabama

Medicare billing

Part B allowed, 2024
$111,796
Medicare patients
536
Services billed
1,381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine69$48,128
LumiganBimatoprost49$16,884
Latanoprost991$11,513
Cyclosporine21$10,265
CombiganBrimonidine Tartrate/Timolol33$7,021
Timolol Maleate286$5,575
Dorzolamide Hcl176$3,102
Travoprost15$2,741
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol25$2,588
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat97$2,312
Brimonidine Tartrate138$1,599
Difluprednate11$963
ErythromycinErythromycin Base79$896
Doxycycline Hyclate14$153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$583$72,034151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 749 optometrist providers in Alabama.

Other optometrist in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →